(Q43228872)

16 November 2017

title

Influence of interferon-beta therapy switching on neutralizing antibody titres: results from the Austrian Switch Study (English)

1 reference

16 November 2017

14

1 reference

16 November 2017

8

Gunther Ladurner

0 references

Franz Fazekas

16

object named as

Franz Fazekas

1 reference

16 November 2017

Claudia Gneiss

1

1 reference

16 November 2017

Pia-Maria Koudouovoh-Tripp

2

1 reference

16 November 2017

Stefan Ropele

3

1 reference

16 November 2017

Thaddäus Gotwald

4

1 reference

16 November 2017

Rainer Ehling

5

1 reference

16 November 2017

Andreas Lutterotti

6

1 reference

16 November 2017

Franz Aichner

7

1 reference

16 November 2017

Gunther Ladurner

8

1 reference

16 November 2017

Christian Eggers

9

1 reference

16 November 2017

Franz Schautzer

10

1 reference

16 November 2017

Bettina Künz

11

1 reference

16 November 2017

Alban Millonig

12

1 reference

16 November 2017

Engelbert Aspeck

13

1 reference

16 November 2017

Thomas Berger

15

1 reference

16 November 2017

Florian Deisenhammer

17

1 reference

16 November 2017

publication date

13 November 2009

1 reference

Multiple Sclerosis Journal

16 November 2017

published in

1 reference

16 November 2017

volume

15

1 reference

16 November 2017

issue

12

1 reference

16 November 2017

page(s)

1481-1488

1 reference

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

16 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1352458509347153

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509347153

Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509347153

Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509347153

The clinical importance of neutralizing antibodies in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509347153

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509347153

Interferon-beta: the neutralizing antibody (NAb) titre predicts reversion to NAb negativity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509347153

Appearance and disappearance of neutralizing antibodies during interferon-beta therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509347153

A novel bioassay for the determination of neutralizing antibodies to IFN-beta1b.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509347153

An Analysis of Neutralization Reaction of Interferon by Antibody: A Proposal on the Expression of Neutralization Titer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509347153

Accurate, robust, and automated longitudinal and cross-sectional brain change analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509347153

Monthly corticosteroids decrease neutralizing antibodies to IFNbeta1 b: a randomized trial in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509347153

Methylprednisolone does not restore biological response in multiple sclerosis patients with neutralizing antibodies against interferon-β.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509347153

The implications of immunogenicity for protein-based multiple sclerosis therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509347153

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458509347153

21 January 2018

Identifiers

DOI

10.1177/1352458509347153

1 reference

16 November 2017

1 reference